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Abstract
Objective The objective of this study was to determine the
magnitude of drug interactions between the hepatitis C
virus (HCV) protease inhibitor boceprevir (BOC) and
antiretroviral (ARV) agents in persons with HIV/HCV co-
infection.
Methods Participants taking two nucleos(t)ide analogs with
either efavirenz, raltegravir, or ritonavir-boosted atazanavir,
darunavir, or lopinavir underwent intensive pharmacoki-
netic (PK) sampling for ARV 2 weeks before (week 2) and 2
weeks after initiating BOC (week 6) and for BOC at week 6.
Geometric mean ratios (GMRs) and 90% confidence
intervals (CIs) were used to compare ARV PK at weeks 2
and 6 and BOC PK at week 6 to historical data (HD) in
healthy volunteers and HCV mono-infected patients.
Results ARV PK was available for 55 participants. BOC
reduced atazanavir and darunavir exposures by 30 and
42%, respectively. BOC increased raltegravir maximum
concentration (Cmax) by 71%. BOC did not alter efavirenz
PK. BOC PK was available for 53 participants. BOC
exposures were similar in these HIV/HCV co-infected
participants compared with HD in healthy volunteers, but
BOC minimum concentrations (Cmin) were lower with all
ARV agents (by 34–73%) compared with HD in HCV
mono-infected patients.
Conclusions Effects of BOC on ARV PK in these HIV/
HCV co-infected individuals were similar to prior studies
in healthy volunteers. However, some differences in the
effects of ARV on BOC PK were observed, indicating the
magnitude of interactions may differ in HCV-infected
individuals versus healthy volunteers. Findings highlight
the need to conduct interaction studies with HCV therapies
in the population likely to receive the combination.
Key Points
The effects of boceprevir on the pharmacokinetics of
several antiretroviral agents were similar in HIV/
hepatitis C virus (HCV) co-infected participants to
those observed in prior studies in healthy volunteers.
Boceprevir exposures were similar in these HIV/
HCV co-infected participants compared with
historical data in healthy volunteers, but significantly
lower boceprevir trough concentrations were
observed with all antiretroviral cohorts compared
with historic values in HCV mono-infected
individuals.
Results highlight some differences in the magnitude
of drug interactions for direct-acting antiviral agents
in healthy volunteers compared with the HCV-
infected population and indicate the need to conduct
interaction studies in the population likely to receive
the combination.
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1 Introduction
Drug interactions are a critical consideration in persons
with HIV and hepatitis C virus (HCV) co-infection. The
potential clinical consequences of an unexpected antiviral
interaction include an increased incidence of adverse
effects or therapeutic failure and the development of viral
resistance. Despite the need to accurately characterize the
extent of antiviral interactions in persons with HIV/HCV
co-infection, there are challenges in studying these inter-
actions in patients, and therefore most interaction studies
are performed in healthy volunteers. However, there are
uncertainties about extrapolating the results of drug inter-
action studies in healthy volunteers to HIV/HCV co-in-
fected patients. The effects of liver functional status on the
magnitude of drug interactions have not been well estab-
lished. Available data suggest pathophysiologic alterations
such as decreased drug uptake into the liver, a reduction in
enzyme expression or function, and alterations in plasma
protein binding can impact the extent of drug interactions
[1]. The objective of this study was to evaluate the mag-
nitude of drug interactions between the HCV NS3/4A
protease inhibitor boceprevir (BOC) and several antiretro-
viral (ARV) agents, including the non-nucleoside reverse
transcriptase inhibitor efavirenz (EFV), the integrase inhi-
bitor raltegravir (RAL), and the ritonavir (RTV)-boosted
protease inhibitors atazanavir (ATV), darunavir (DRV) and
lopinavir (LPV), in persons with HIV and HCV co-
infection.
2 Methods
AIDS Clinical Trials Group (ACTG) study A5309s was an
intensive pharmacokinetic (PK) substudy of ACTG A5294
(NCT01482767), a prospective, phase 3, open-label study
of BOC, peginterferon alfa-2b, and ribavirin in HCV/HIV
co-infected participants [2]. Both A5294 and A5309s were
approved by institutional review boards at the ACTG study
sites. All participants provided written informed consent.
All study procedures were in accordance with the Helsinki
Declaration of 1975, as revised in 2000.
2.1 Subjects
Persons with HIV/HCV co-infection receiving peginter-
feron alfa-2b 1.5 mg/kg subcutaneously once a week and
ribavirin 800–1400 mg daily based on body weight,
administered in two divided doses, and intending to initiate
BOC 800 mg three times daily with food could participate
in this PK substudy. Allowed ARV regimens included two
nucleoside reverse transcriptase inhibitors plus one of the
following: EFV 600 mg once daily, RAL 400 mg twice
daily, ATV/RTV 300/100 mg once daily, DRV/RTV
600/100 mg twice daily, or LPV/RTV 400/100 mg twice
daily. Participants could be naı¨ve to HCV treatment or
have failed prior interferon-based therapy. Participants
with Child-Pugh class A cirrhosis (documented by liver
biopsy or FibroSureTM) were allowed provided they had no
evidence of decompensated disease or hepatocellular car-
cinoma and platelet counts of greater than 80 9 109/L.
Medications other than ARV with the potential to signifi-
cantly alter BOC PK or be altered by BOC were excluded.
2.2 Design
Participants underwent intensive PK sampling for ARV 2
weeks before (week 2) and 2 weeks after initiating BOC
(week 6), and intensive PK sampling for BOC at week 6.
For these intensive PK visits, participants were admitted in
the morning following an 8-h fast and offered a partially
standardized breakfast (three options with similar fat and
calorie content, 21 g and 600 kcal, respectively). Dosing of
ARV and BOC (at week 6) was directly observed. Samples
were collected at pre-dose and 1, 2, 3, 4, 6, and 8 h post-
dose, and 12 and 24 h post-dose for twice daily and once
daily ARV, respectively. Participants taking EFV and
ATV/RTV in the evenings switched to morning dosing at
least 3 days prior to the intensive PK visits. Adherence in
the 3 days prior to the intensive PK visits was assessed
using a medication diary.
2.3 Bioanalyses
2.3.1 Boceprevir (BOC) in Plasma
Blood samples for BOC quantification were cooled in an
ice bath, approximately 4 C, and then centrifuged for 15
min at 1500g within 30 min of collection. Following cen-
trifugation, 1.5 mL of plasma was placed in pre-chilled
cryovials containing 75 lL of 85% phosphoric acid. The
vials were capped, mixed well and kept on wet ice until
placed in a freezer for storage at -20 C or colder.
BOC is administered as an approximately equal mixture
of two diastereomers, SCH534128 (pharmacologically
active) and SCH534129 (inactive), which rapidly inter-
convert in plasma. BOC concentrations are reported as the
sum of SCH534128 and SCH534129, which were quanti-
fied by a validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) method (PPD, Middleton, WI,
USA). SCH534128 and SCH534129 and internal standards
(IS) 503034-d9 and 629144-d9 were isolated by solid-phase
extraction and eluted from the solid-phase extraction plate.
The extracts were dried and reconstituted. The final extract
was analyzed by LC-MS/MS using positive ion
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atmospheric pressure chemical ionization. The assay was
validated over the SCH534128 concentration range of 5.20
to 5200 ng/mL and over the SCH534129 concentration
range of 4.80 to 4800 ng/mL. SCH534128 assay impreci-
sion (% CV) was B12.1%, and inaccuracy (bias, % dif-
ference) was within -7.12 to 3.59%. SCH534129 assay
imprecision (% CV) was B10.3%, and inaccuracy (bias, %
difference) was within -7.84 to 4.12% [3].
2.3.2 Antiretroviral (ARV) Agents in Plasma
ARV concentrations were determined using validated
methods at the University at Buffalo Pharmacology Spe-
cialty Laboratory. DRV, EFV and LPV were measured
using high performance liquid chromatography with
ultraviolet detection (HPLC/UV) linear in the range of
0.100–16.0 mg/L for DRV and EFV, and 0.200–16.0 mg/L
for LPV [4]. RAL, ATV, and RTV were measured using
ultraperformance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS). Methods were validated
using the Food and Drug Administration (FDA) bioana-
lytical guidance recommendations and externally reviewed
for acceptance [5].
After addition of 750 lL of acetonitrile and 25 lL of the
working IS solution (ATV-d5 and RTV-d6) to 250 lL of
ethylenediaminetetraacetic acid (EDTA) human plasma,
ATV and RTV were extracted via protein precipitation.
The compounds were separated under gradient conditions
and detected via electrospray coupled to a triple quadrupole
mass spectrometer. Multiple reaction monitoring in posi-
tive mode was used, with ATV monitored at 706/168,
ATV-IS at 711/144, RTV at 722/140 and RTV-IS at
728/146. The range of quantitation was 10–4000 ng/mL for
both ATV and RTV; samples over the upper limit of
dilution were diluted and reassayed. ATV assay impreci-
sion (% CV) was B3.5%, and inaccuracy (bias, % differ-
ence) was within -13 to –6.3%. RTV assay imprecision
(% CV) was B6.1%, and inaccuracy (bias, % error) was
within -9.8 to – 8.6 %.
For analysis of RAL, plasma samples were prepared
using an Oasis HLB 96-well solid phase extraction (Waters
Corp., Milford, MA, USA) and included the addition of
deuterated working IS solution to 250 lL of EDTA human
plasma. Prior to sample extraction, samples were buffered
with 250 lL of a 4% formic acid solution, and after elution,
the eluant was diluted with 0.05% formic acid. The com-
pounds were chromatographed under gradient conditions
and detected via electrospray coupled to a triple quadrupole
mass spectrometer. Multiple reaction monitoring in posi-
tive mode was used, with RAL monitored at 445/361 and
RAL-d3 at 448/364. The range of quantitation was 10–4000
ng/mL for RAL; samples over the upper limit of dilution
were diluted and reassayed.
The laboratory participated successfully in proficiency
testing programs for all compounds throughout the analysis
period to assure accuracy and specificity [6–8].
2.4 Pharmacokinetic Analysis
Area under the concentration–time curve over the dosing
interval (AUC0–T) (8, 12, or 24 h) was estimated using the
linear trapezoidal rule. If the pre-dose sample (Cpre) was
missing, the concentration at the end of the dosing interval
(CT) was substituted for the Cpre in the calculation of
AUC0–T. If the C T was missing, the Cpre was substituted in
the calculation of the AUC0–T. For participants who
appeared to re-dose prior to obtaining the CT (i.e., when CT
was more than 40% higher than the concentration at the
previous sampling time), Cpre was substituted for the CT in
the calculation of the AUC0–T in order to minimize over-
estimation of AUC0–T. Maximum concentration (Cmax) and
minimum concentration (Cmin) were observed. Data were
excluded from analysis if (1) participants missed more than
one BOC or ARV dose in the 3 days leading up the
intensive PK visits, (2) more than two samples were
missing from the intensive PK profile, or (3) both the Cpre
and CT were missing.
2.5 Statistical Analysis
Geometric mean ratios (GMRs) and associated 90% con-
fidence intervals (CIs) were used to compare ARV PK with
versus without BOC (within-subject comparisons, week 6
vs week 2) and BOC PK at week 6 versus historical data in
healthy volunteers. 90% CIs around the GMR were used as
per FDA guidance [9], and 90% CIs excluding 1 were
considered statistically significant. 90% CIs are nominal
without adjustment for multiple comparisons. Historical
data from healthy volunteers were used as the primary
comparator because no intensive PK data from persons
with HCV who received the commercial dose and formu-
lation were available. The PK parameters in the BOC
prescribing information [10] are values obtained from
intensive sampling in healthy volunteers. BOC population
PK modeling was previously performed in persons with
HCV using samples and data obtained through sparse
sampling in the phase 2 and 3 trials [11]. Formal statistical
comparisons were performed with the BOC PK in healthy
volunteers since these data were generated in a manner
consistent with A5309s (i.e., from intensive sampling and
non-compartmental analysis). However, the historical data
from both healthy volunteers and the modeled data from
HCV-infected subjects are provided and discussed for
interpretation of study results. GMRs were used to compare
BOC PK at week 6 versus historical modeled BOC data in
HCV mono-infected patients.
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3 Results
3.1 Participants
The first participant enrolled in A5309s in May 2012.
Target enrollment for A5309s was 100 participants (20 in
each of the ARV cohorts); however, the parent study
A5294 closed to enrollment on December 20, 2013 because
the study team and FDA determined the primary objectives
could be addressed with adequate power using a reduced
sample size. At that time, sixty-four participants were
enrolled in A5309s: 24 on EFV, 22 on RAL, 11 on ATV/
RTV, five on DRV/RTV, and two on LPV/RTV. Partici-
pant demographics are shown in Table 1. Most participants
(88%) were male. Sixty-four percent of participants were
HCV treatment naı¨ve and 16% were cirrhotic. ARV PK
was available for 55 participants, and BOC PK was
available for 53 participants. A CONSORT diagram is
provided in Fig. 1.
3.2 ARV Pharmacokinetics
Mean [standard deviation (SD)] ARV PK parameters with
and without BOC, and the change in ARV PK with BOC,
are shown in Table 2. BOC did not alter EFV PK. RAL
AUC0–T and Cmax were 46 and 71% higher, respectively,
when administered with BOC, but there was wide vari-
ability in RAL PK, such that differences were not statis-
tically significant. BOC reduced ATV AUC0–T and Cmin by
30 and 43%, respectively. BOC reduced DRV AUC0–T,
Cmax, and Cmin by 42, 32, and 64%, respectively. In the two
participants on LPV/RTV, mean (SD) LPV AUC0–T, Cmax,
and Cmin were 67.62 (42.69) mg*h/L, 7.60 (4.40) mg/L,
and 2.76 (3.63) mg/L, respectively, without BOC and 57.18
(2.62) mg*h/L, 7.28 (0.40) mg/L, and 1.90 (0.22) mg/L,
respectively (not tabulated) with BOC, suggesting BOC
reduced LPV concentrations. Figure 2 summarizes ARV
concentration–time curves with and without BOC, and
shows within-participant differences in ARV AUC with
versus without BOC. RTV was also reduced with BOC.
With ATV/RTV, the RTV AUC0–T and Cmin were reduced
44 and 69%, respectively. With DRV/RTV, RTV AUC0–T
and Cmin were reduced 35 and 37%, respectively.
3.3 BOC Pharmacokinetics
Mean (SD) week 6 BOC PK by ARV cohort are shown in
Table 3. To estimate the GMR and 90% CI, BOC PK was
compared to historical data in 71 healthy volunteers [10].
In 71 healthy volunteers, mean (SD) BOC AUC0–T, Cmax,
and Cmin were 5.41 (1.47) mg*h/L, 1.72 (0.42) mg/L, and
0.09 (0.06) mg/L, respectively. BOC AUC0–T, Cmax, and
Table 1 Participant demographics (n = 64)
Total
(n = 64)
EFV
(n = 24)
RAL
(n = 22)
ATV/RTV
(n = 11)
DRV/RTV
(n = 5)
LPV/RTV
(n = 2)
Age (years), mean (SD) 50.2 (7.7) 50.2 (6.4) 49.2 (8.1) 52.6 (9.2) 50.6 (8.2) 46.0 (12.7)
Weight (kg), mean (SD) 82.9 (16.5) 80.3 (14.9) 86.4 (20.9) 83.3 (11.7) 79.9 (13.7) 81.3 (17.4)
Male, number (%) 56 (88%) 19 (79%) 19 (86%) 11 (100%) 5 (100%) 2 (100%)
Race, number (%)
White non-Hispanic 29 (45) 8 (33) 12 (55) 5 (45) 3 (60) 1 (50)
Black non-Hispanic 25 (39) 11 (46) 7 (32) 5 (45) 1 (20) 1 (50)
Hispanic 7 (11) 5 (21) 2 (9) 0 (0) 0 (0) 0 (0)
Other 3 (5) 0 (0) 1 (4) 1 (10) 1 (20) 0 (0)
Cirrhotic, number (%) 10 (16) 4 (17) 4 (18) 2 (18) 0 (0) 0 (0)
HCV treatment experienced, number (%) 23 (36) 12 (50) 5 (23) 3 (27) 3 (60) 0 (0)
Baseline HIV-1 RNA\50 copies/mL,
number (%)
62 (98) 24 (100) 20 (95)* 11 (100) 5 (100) 2 (100)
Baseline CD4 (cells/mm3), mean (SD) 662.1 (292.3) 596.6 (239.9) 583.7 (193.9) 847.2 (434.3) 870.4 (359.8) 772.5 (94.0)
NRTI regimen, number (%)
Tenofovir disoproxil fumarate/
emtricitabine
50 (78) 20 (83) 17 (77) 8 (73) 4 (80) 1 (50)
abacavir/lamivudine 12 (19) 3 (13) 5 (23) 2 (18) 1 (20) 1 (50)
Other 2 (3) 1 (4) 0 (0) 1 (9) 0 (0) 0 (0)
ATV atazanavir, DRV darunavir, EFV efavirenz, HCV hepatitis C virus, LPV lopinavir, NRTI nucleoside reverse transcriptase inhibitor, RAL
raltegravir, RTV ritonavir, SD standard deviation
* Baseline HIV-1 RNA missing for one subject on RAL
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Cmin were lower in participants on EFV by 12, 29, and
22%, respectively, compared with BOC PK in healthy
volunteers. BOC AUC0–T in those on RAL was 17% higher
than the AUC0–T in healthy volunteers. BOC Cmin in those
on ATV/RTV was 31% higher than in healthy volunteers,
but the BOC AUC0–T and Cmax were not different. BOC
AUC0–T and Cmax were not different in those on DRV/RTV
relative to these values in healthy volunteers; however, the
BOC Cmin in those on DRV/RTV was 93% higher than the
BOC Cmin in healthy volunteers. Mean (SD) BOC AUC0–T,
Cmax, and Cmin in the two participants on LPV/RTV were
3.69 (1.25) mg*h/L, 0.98 (0.27) mg/L, and 0.06 (0.02) mg/L,
respectively (not tabulated). These values appear lower than
the BOC AUC0–T, Cmax, and Cmin in healthy volunteers.
As previously described, there are no intensive PK data
in HCV-infected persons receiving the marketed BOC dose
and formulation. However, there are BOC AUC0–T, Cmax,
and Cmin estimates generated through population PK
modeling of samples obtained in phase 2 and 3 studies [11].
Population PK modeling of samples obtained through BOC
trials determined a mean (SD) BOC AUC0–T, Cmax, and
Cmin in 271 HCV-infected patients to be 4.65 (1.58) mg*h/L,
1.1 (0.4) mg/L, and 0.23 (0.11) mg/L, respectively. These
AUC0–T and Cmax estimates are lower than those observed
in healthy volunteers, while the estimated Cmin in HCV-
infected persons was higher than that observed in healthy
volunteers (0.23 vs 0.09 mg/L). If BOC PK in the ARV
cohorts in A5309s were compared to these modeled data in
HCV-infected persons rather than healthy volunteers, the
mean BOC Cmin in all ARV cohorts appears lower than the
mean modeled Cmin of 0.23 mg/L (Fig. 3).
4 Discussion
This study determined the magnitude of antiviral interac-
tions in individuals with chronic liver disease and HIV co-
infection. A 16–43% reduction in ATV concentrations and
a 32–64% reduction in DRV concentrations were observed
with the addition of BOC. There was no effect of BOC on
EFV. In contrast to a previous study in healthy volunteers
which found no effect of BOC on RAL PK [10], we
observed an increase in RAL concentrations, though there
was wide variability in RAL concentrations and the results
were only statistically significant for Cmax. In terms of the
effects of ARV on BOC PK, interpretation is dependent on
Enrolled (n=64)
Excluded from PK analyses (n=7)
• Discontinued before week 6 (n=2)
• Lost to follow-up (n=2)
Inadvertently enrolled• (n=1)
• PK samples not received (n=1)
• Non-adherent (n=1)
Excluded from ARV PK analyses (n=2)
• Medication dosing error (n=1)
• ARV PK not collected (n=1)
ARV PK (n=57)
Excluded from BOC PK analyses (n=4)
• Medication dosing error (n=2)
• Missing Cpre and CƮ samples (n=1)
• Samples too viscous for quantification (n=1)
BOC PK (n=57)
ARV PK Analysis Eligible (n=55) BOC PK Analysis Eligible (n=53)
Fig. 1 CONSORT diagram showing subject disposition for PK analysis. ARV antiretroviral, BOC boceprevir, Cpre pre-dose sample, PK
pharmacokinetic(s)
Boceprevir and Antiretroviral PK Interactions in HIV/HCV Co-infected Persons 561
the historical comparator. Relative to BOC PK in healthy
volunteers, BOC Cmin was 31 and 93% higher in these
HIV/HCV co-infected individuals receiving ATV/RTV and
DRV/RTV, BOC AUC was 17% higher in those on RAL,
and BOC Cmax was 29% lower in those on EFV. When
compared with historical PK estimates using population PK
modeling with sparse collection in HCV mono-infected
subjects, the BOC Cmin in all ARV cohorts was numeri-
cally lower than the modeled mean Cmin of 0.23 mg/L.
The effect of BOC on ATV/RTV, DRV/RTV, and EFV
PK in these HIV/HCV co-infected individuals was very
similar to that observed in prior studies in healthy volun-
teers (Table 4). The mechanism(s) by which BOC reduces
concentrations of RTV-boosted HIV protease inhibitors is
unclear. BOC is a potent CYP3A4 inhibitor in vivo. The
Cmax and AUC for the CYP3A probe, midazolam, were
increased 2.77-fold and 5.3-fold by BOC [10]. In vitro,
BOC was not found to induce CYP enzymes [12]. How-
ever, both the AUC and Cmax of escitalopram, a known
substrate of CYP2C19, were reduced approximately 20%
in the presence of BOC [13]. Escitalopram’s mean half-life
was also accelerated from 31 to 22 h [13]. BOC was also
found to increase metabolite formation of the HIV non-
nucleoside reverse transcriptase inhibitor, etravirine, in a
prior study [14], suggesting BOC may potentially induce
CYP enzymes. Reductions in RTV concentrations by
25–69% likely contributed to the reductions in ATV, DRV,
and LPV concentrations in our participants.
RAL AUC and Cmax were increased 46 and 71% with
the addition of BOC in these HIV/HCV co-infected par-
ticipants. Though this effect on AUC did not reach statis-
tical significance due to the wide interpatient variability in
RAL PK, these increases are greater than previously
observed in healthy volunteers (4 and 11%, respectively)
[15]. Explanations for the discrepancy are unclear, but the
prior study included a single dose of RAL in healthy vol-
unteers, whereas our HIV-infected participants were
receiving RAL as a component of their chronically sup-
pressive ARV therapy. RAL is metabolized by uridine
glucuronosyl transferase 1A1 (UGT1A1), but in vitro,
Table 2 Mean (SD) antiretroviral pharmacokinetics and GMR (90% CI) with vs without BOC
No. No BOC
(week 2)
With BOC
(week 6)
GMR
(90% CI)
GMR point estimate expressed as
percentage change from week 2 (%)
ATV/RTV
ATV AUC 11 35.20 (21.21) 23.75 (12.37) 0.70 (0.55–0.87)* ;30
ATV Cmax 11 2.66 (1.61) 2.14 (1.00) 0.84 (0.62–1.14) ;16
ATV Cmin 11 0.72 (0.48) 0.42 (0.35) 0.57 (0.42–0.76)* ;43
RTV AUC 11 7.57 (3.82) 4.07 (1.45) 0.56 (0.46–0.68)* ;44
RTV Cmax 11 0.80 (0.54) 0.55 (0.20) 0.75 (0.54–1.04) ;25
RTV Cmin 11 0.06 (0.04) 0.03 (0.03) 0.31 (0.23–0.43)* ;69
DRV/RTV
DRV AUC 5 67.07 (14.58) 38.85 (9.40) 0.58 (0.53–0.63)* ;42
DRV Cmax 5 7.81 (1.45) 5.29 (1.02) 0.68 (0.64–0.71)* ;32
DRV Cmin 5 4.00 (1.24) 1.42 (0.46) 0.36 (0.27–0.48)* ;64
RTV AUC 5 6.87 (3.14) 4.51 (1.92) 0.65 (0.55–0.78)* ;35
RTV Cmax 5 0.94 (0.51) 0.67 (0.28) 0.74 (0.52–1.04) ;26
RTV Cmin 5 0.3 (0.17) 0.19 (0.12) 0.63 (0.50–0.79)* ;37
Efavirenz
AUC 18 81.98 (76.82) 86.50 (73.76) 1.09 (0.97–1.22) :9
Cmax 18 4.72 (3.42) 5.05 (3.31) 1.10 (0.97–1.24) :10
Cmin 18 2.60 (3.09) 2.80 (2.91) 1.11 (0.96–1.27) :11
Raltegravir
AUC 19 5.26 (7.11) 7.01 (5.12) 1.46 (1.00–2.12) :46
Cmax 19 1.14 (1.57) 1.75 (1.41) 1.71 (1.08–2.70)* :71
Cmin 19 0.09 (0.08) 0.09 (0.07) 1.09 (0.75–1.58) :9
AUC is in mg*h/L, Cmax and Cmin in mg/L; DRV/RTV is given as 600/100 mg twice daily. LPV/RTV not reported due to small sample size
(n = 2)
; decrease, : increase, ATV atazanavir, AUC area under the concentration–time curve, BOC boceprevir, CI confidence interval, Cmax maximum
concentration, Cmin minimum concentration, DRV darunavir, GMR geometric mean ratio, LPV lopinavir, RTV ritonavir, SD standard deviation
* GMR CI excludes 1.0
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Fig. 2 ARV pharmacokinetics
with vs without BOC. Left panel
summary concentration-time
plots for ARVs without (solid
yellow line) and with (dashed
purple line) concurrent BOC
administration; geometric
means of all subjects’ hour-
specific concentrations are
plotted on the log scale. Right
panel subject-specific ARV
AUC0–T without vs with BOC
are plotted and connected. ARV
antiretroviral, AUC0–T area
under the concentration–time
curve over the dosing interval,
BOC boceprevir
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BOC does not inhibit UGT1A1 [12]. Also, RAL Cmin was
not increased, which indicates BOC may increase the
bioavailability of RAL either at the level of the gut or
hepatic uptake. RAL is a substrate for P-glycoprotein (P-
gp) and breast cancer resistance protein (BCRP) [16], but
not human organic anion transporting polypeptide 1B1
(OATP1B1) [17]. BOC is only a weak inhibitor of P-gp, as
evidenced by a 19% increase in the AUC of digoxin, a P-gp
probe substrate [10]. BOC is a weak inhibitor of BCRP
in vitro [18], but there are no data in vivo with BCRP probe
substrates. RAL has a wide therapeutic index; thus it is
unlikely that a 46% increase in RAL AUC and 71%
increase in RAL Cmax would have clinical implications.
Prior interaction studies in healthy volunteers found
32–35 and 45–57% lower BOC concentrations with DRV/
RTV and LPV/RTV, respectively. BOC is a substrate of
aldo-keto reductase (AKR) enzymes 1C2 and 1C3 and a
substrate for CYP3A4. The mechanism for this effect is
unclear, but may be due to induction of transporters or
enzymes that transport or metabolize BOC or perhaps a
protein binding displacement interaction whereby total
concentrations of BOC are reduced while unbound con-
centrations are unchanged. Despite the magnitude of the
interaction observed in healthy volunteers, similar rates of
sustained virologic response (SVR or cure) were observed
in HIV-infected patients (86% of whom were on a RTV-
boosted HIV protease inhibitor) in the phase 2 study of
peginterferon alfa-2b, ribavirin, and BOC to SVR rates
observed in HCV mono-infected patients [19]. This raises
the question as to whether the magnitude of antiviral drug
interactions is the same in persons with HCV (and potential
hepatic impairment) as in healthy volunteers. EFV was also
found to reduce BOC Cmin, by 44%, in healthy volunteers
through induction of CYP3A4 [10]. RAL did not change
BOC AUC and Cmax in a prior study in healthy volunteers
[10]. Our study determined the effects of ARV on BOC by
comparing BOC PK in HIV/HCV co-infected participants
to historical data. While we might have expected greater
reductions in BOC concentrations in those on DRV/RTV,
LPV/RTV and EFV based on the prior studies in healthy
volunteers, only the two participants on LPV/RTV had
BOC concentrations lower than in healthy volunteers. BOC
concentrations were only 12–29% lower in those on EFV
relative to BOC concentrations in healthy volunteers, and
BOC AUC and Cmin were actually higher relative to
healthy volunteers in those on ATV/RTV and DRV/RTV.
In those on RAL, BOC AUC was 17% higher than in
healthy volunteers. If we compare the BOC PK in our HIV/
HCV co-infected individuals to modeled data in HCV
mono-infected individuals, however, BOC Cmin was lower
in all ARV cohorts. BOC Cmin was 73, 56, 56, and 34%
lower in those on EFV, RAL, ATV/RTV, and DRV/RTV,
respectively.
This study, A5309s, was an intensive PK substudy of
ACTG A5294 (NCT01482767). A5294 was a prospective,
phase 3, open-label study of BOC, peginterferon alfa-2b,
Table 3 Mean (SD) week 6 BOC PK by ARV cohort
ARV No. Week 6
BOC PK
GMR (90% CI) vs historical
data in healthy volunteers
GMR point
estimate (%)
GMR vs modeled historical
data in HCV? mono-infected
individuals
BOC AUC EFV 19 4.80 (1.39) 0.88 (0.78–0.99) ;12 1.05
BOC Cmax 19 1.30 (0.63) 0.71 (0.61–0.84)* ;29 1.17
BOC Cmin 19 0.10 (0.09) 0.78 (0.49–1.24) ;22 0.27
BOC AUC RAL 18 6.35 (1.96) 1.17 (1.04–1.32)* :17 1.39
BOC Cmax 18 1.76 (0.48) 1.00 (0.88–1.15) $ 1.65
BOC Cmin 18 0.12 (0.09) 1.29 (0.95–1.76) :29 0.44
BOC AUC ATV/RTV 10 5.57 (1.22) 1.04 (0.90–1.20) :4 1.23
BOC Cmax 10 1.74 (0.66) 0.97 (0.76–1.23) ;3 1.59
BOC Cmin 10 0.10 (0.03) 1.31 (1.05–1.64)* :31 0.44
BOC AUC DRV/RTV 4 5.56 (1.68) 1.03 (0.72–1.46) :3 1.22
BOC Cmax 4 1.51 (0.54) 0.85 (0.54–1.36) ;15 1.41
BOC Cmin 4 0.15 (0.07) 1.93 (1.37–2.73)* :93 0.66
To determine the GMR and 90% CI, BOC PK were compared to historical data in 71 healthy volunteers. Mean (SD) BOC AUC, Cmax, and Cmin
in healthy volunteers are 5.41 (1.47) mg*h/L, 1.72 (0.42) mg/L, and 0.09 (0.06) mg/L, respectively. LPV/RTV not reported due to small sample
size (n = 2)
; decrease, : increase, $ no change, ARV antiretroviral, ATV atazanavir, AUC area under the concentration–time curve, BOC boceprevir, CI
confidence interval, Cmax maximum concentration, Cmin minimum concentration, DRV darunavir, EFV efavirenz, GMR geometric mean ratio,
HCV hepatitis C virus, LPV lopinavir, PK pharmacokinetics, RAL raltegravir, RTV ritonavir, SD standard deviation
* GMR excludes 1.0
564 J. J. Kiser et al.
and ribavirin in HCV/HIV co-infected subjects [2]. The
SVR rates in 135 treatment naı¨ve and 122 treatment
experienced participants were 36 and 30%, respectively.
This SVR rate is significantly lower than that observed in
the phase 2 trial of HIV/HCV co-infected participants
(63%) [19] and lower than historical SVR rates observed in
phase 3 trials of HCV mono-infected individuals (59–66%)
[20, 21]. The majority of patients in A5294 were on EFV
(42%) or RAL-containing (36%) ARV therapy. There was
no signal of a particular ARV cohort having lower SVR
rates; to the contrary, treatment naı¨ve participants taking
ATV/RTV had the highest rate of SVR observed in the
study at 61%, but there were only 18 participants in this
category. The strongest predictor of treatment outcome in
A5294 was race, with blacks having significantly lower
SVR rates. Roughly half of the A5294 participants were
black.
This study evaluated the drug interaction potential of
HCV and HIV medications in the patient population
receiving the combination in clinical practice. This is a
significant advantage in terms of the generalizability of
study findings; however, there are some limitations. Given
these are HIV-infected individuals on suppressive ARV
therapy, ARV therapy was not discontinued in order to
determine the PK of BOC alone, and thus BOC PK was
compared to historical data. There were challenges with
our BOC historical comparators since there were no
intensive PK data in HCV-infected individuals on the
commercial dose and formulation of BOC. There were also
very few participants on RTV-boosted HIV protease inhi-
bitors in this substudy, since recruitment was a function of
enrollment in the parent study and the parent study opened
first to those on EFV and RAL and HIV protease inhibitors
were added in version 2.0. Given BOC was combined with
pegylated interferon, which is not indicated in persons with
decompensated (Child Pugh B or C) cirrhosis, there were
very few participants in our study with more advanced liver
disease. Advanced liver disease can be associated with
portal hypertension which causes shunting of drug around
the liver, reductions in hepatic uptake transporter and
enzyme expression or function, and reductions in plasma
protein binding due to a decrease in the amount of proteins
synthesized, but also the quality of protein and competition
for binding with endogenous substances (e.g., bilirubin).
Sixteen percent of the participants had Child Pugh A cir-
rhosis, but the majority were non-cirrhotic. The magnitude
of the interactions observed may differ in those with more
advanced disease.
5 Conclusions
Overall, we found the effect of BOC on RTV-boosted HIV
protease inhibitors and EFV PK in these HIV/HCV co-
infected participants to be very similar to that observed in
healthy volunteers, but BOC appeared to increase RAL
Fig. 3 Boceprevir Cmin relative to HD in healthy volunteers (HD
HCV-) and modeled data in HCV mono-infected patients (HD
HCV?). Minimum, maximum and median, and 25th and 75th
percentiles are shown as boxes and whiskers; means are indicated by
diamond symbols. Individual subject values are also plotted: HCV-
treatment naı¨ve patients (open circles) and HCV-treatment experi-
enced patients (? symbols). ATV atazanavir, Cmin minimum concen-
tration, DRV darunavir, EFV efavirenz, HCV hepatitis C virus, HD
historical data, LPV lopinavir, RAL raltegravir, rtv ritonavir
Table 4 Boceprevir interactions with antiretroviral agents in prior studies in healthy volunteers
Antiretroviral pharmacokinetics Boceprevir pharmacokinetics References
DAUC (%) DCmax (%) DCmin (%) DAUC (%) DCmax (%) DCmin (%)
ATV/RTV ;35 ;25 ;49 ;5 ;7 ;18 [22]
BID DRV/RTV ;44 ;36 ;59 ;32 ;25 ;35 [22]
BID LPV/RTV ;34 ;30 ;43 ;45 ;50 ;57 [22]
EFV :20 :11 ND ;19 ;8 ;44 [10]
RAL :4 :11 ;25 ;2 ;4 ;26 [10]
The table shows the change (D) in AUC, Cmax and Cmin for boceprevir and the antiretroviral agents
; decrease, : increase, ATV atazanavir, AUC area under the concentration–time curve, BID twice daily, Cmax maximum concentration, Cmin
minimum concentration, DRV darunavir, EFV efavirenz, LPV lopinavir, ND not determined, RAL raltegravir, RTV ritonavir
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concentrations. While BOC PK in our participants was
comparable to BOC PK in healthy volunteers, the BOC
Cmin was lower in all ARV cohorts compared with his-
torical data in HCV mono-infected patients. Additional
PK-pharmacodynamic analysis would be required to
determine whether BOC exposures contributed to the low
rates of SVR observed in A5294; however, BOC is no
longer marketed, and several newer HCV therapies have a
lower potential for drug interactions with ARV.
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